Karen Mullins, D.O. University of Tennessee Knoxville Neurology Clinic.

Slides:



Advertisements
Similar presentations
 Most common and important degenerative disease of the brain  Shrinkage in size and weight of the brain  Severe degree of diffuse cerebral atrophy.
Advertisements

Management of Early Dementia Dr Eleanor Mullan Consultant Psychiatrist Mental Health Services for Older People South Lee, Cork Feb 2011.
Dementia with Lewy bodies The more who know, the fewer who suffer.
Parkinson’s Disease (PD)
Frontotemporal Dementia
Martha Stearn, MD Institute for Cognitive Health St John’s Medical Center Jackson, Wyoming.
Mr. Chris Webb. Overview Dementia is a common condition. In England there are currently 570,000 people living with dementia. That number is expected to.
Dementia and Aging Steven Huege, M.D Assistant Professor of Clinical Psychiatry Perelman School of Medicine at the University of Pennsylvania.
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
Dementia Drugs: Mainstream and Alternative Medicines Susan Kurrle.
Parkinson’s Disease Dementia (PDD) A Clinical Perspective
Dementia with Lewy Bodies
Alexander I. Tröster, Ph.D. Department of Neurology
LEWY BODY DEMENTIA Hena Jawaid PGY-III. Also known as …. LBD - hena jawaid 2  Cortical lewy body disease  Lewy body variant of Alzheimer’s disease 
Introduction to neuropsychiatric disorders
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Cognitive Enhancers. Dementia A syndrome due to disease of the brain, characterised by progressive, global deterioration in intellect including: Memory.
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.
Chapter 15 - Cognitive Disorders I.Delirium Acute, temporary impairment in perception & cognition Fluctuating course.
Alzheimer’s Disease Angela Singh, PharmD Associate Professor of Pharmacy Practice Florida A&M University College of Pharmacy & Pharmaceutical Sciences.
Burcu Ormeci, MD Department of Neurology.  In the United States;  As many as 7 million people have dementia  Almost half of all people age 85 and older.
Treatment of Parkinson’s Disease Dementia (PDD) Shanil Ebrahim.
Pharmacological Management. Only symptomatic treatment, there is no cure. Acetylcholinesterase inhibitors - Only for mild to moderate dementia –Donepezil.
Lewy body dementia: When it isn’t Alzheimer’s (Speaker’s name here)
Non-Alzheimer’s Dementias
Introduction to neuropsychiatric disorders
THE COGNITIVE DISORDERS Brian E. Wood, D.O. Associate Professor and Chair Department of Neuropsychiatry and Behavioral Sciences Edward Via Virginia College.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 33 Delirium and Dementia.
 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer’s is the most common form of dementia. This.
10 signs to early detection 1. Memory loss that affects daily life 2. Challenges in planning or solving problems 3. Difficulty completing projects at.
CONFUSION & DEMENTIA CHAPTER 35.
CU-1 Summary of Neuropathological and Clinical Features of PDD Clive Ballard, MD Professor of Age Related Diseases Institute of Psychiatry King’s College.
HOW TO EXAMINE PATIENTS WITH DEMENTIA Serge Gauthier, MD, FRCPC McGill Centre for Studies in Aging Douglas Mental Health Research Institute.
The Dementias Dr Giles Richards Consultant Psychiatrist CFT.
A neurology primer. Hospital for Mentally Ill & Epileptics (Frankfurt )
Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Assessment and Diagnosis of Dementia Dr Alison Haddow.
CAROLINE HARADA, M.D. ASSOCIATE PROFESSOR OF MEDICINE UAB DIVISION OF GERONTOLOGY, GERIATRICS, AND PALLIATIVE CARE NOVEMBER 2013 Dementia.
DEMENTIA ABDULMAJEED ALOLAYAH What is DEMENTIA ? It is a chronic global impairment of cognitive functions without disturbed consciousness.
Amyotrophic lateral sclerosis
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
Dementia Nicholas Cascone, PA-C.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Alzheimer’s disease.
Used to be called Dementia Neurocognitive Disorders.
Orientation to Early Memory Loss. Let’s look for some answers… What is happening? What should I do? Where should I go?
Seniors with Memory Loss: A Primer Praveen Dayalu, MD Clinical Associate Professor Department of Neurology University of Michigan.
Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.
DEGENERATIVE DISEASES is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether.
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
The Malfunctioning Mind: Degenerative Diseases of the Brain
Anne Moore Specialist in Special Care NHS Lanarkshire PDS
59 year old man w visual hallucinations
Dementia with Lewy Bodies
Neurodegenerative Disorders
The Malfunctioning Mind: Degenerative Diseases of the Brain
Dementia Jaqueline Raetz, M.D..
Unit 40 Dementia care.
Dementia Jaqueline Raetz, M.D..
פסיכוגריאטריה ד''ר שורצמן בי''ח פלימן.
Atypical Parkinsonian Syndromes
Chapter 30 Delirium and Dementia
Drugs for Degenerative Diseases of the Nervous System
Parkinson’s Disease Definitions Disease features Pathology
Presentation transcript:

Karen Mullins, D.O. University of Tennessee Knoxville Neurology Clinic

Lecture Objectives Describe clinical presentations of Lewy Body and Parkinson’s Associated Dementia(PAD) Describe pathophysiological mechanisms associated with Lewy Body Dementia (LBDD) and PAD Review both pharmacologic and nonpharmacologic treatments for LBDD and PAD

Clinical Presentation Of LBD Fluctuations in cognitive function Varying levels of alertness and attention Excessive daytime drowsiness or daytime sleep >2 hours Episodes of staring off into space Episodes of disorganized speech

Clinical Presentation Of LBD Visual hallucinations Delusions REM sleep behavior disorder Impaired excecutive function, visuospatial function (Stroop, digit span backwards)

Clinical Presentation of LBD Parkinsonism Appears early in course of disease May not be enough to meet full criteria for PD Less frequent rest tremor May see myoclonus Orthostatic hypotension

Clinical Presentation LBD Capgras syndrome: delusion that people in the environment are not themselves but actually doubles Also see passive personality traits- decreased emotional responsivity, lack of interest in hobbies, increasing apathy, purposeless hyperactivity

Diagnostic Criteria Dementia with Lewy Bodies (DLB) Consensus diagnostic criteria for DLB were first established in 1996 Dementia accompanied by ≥ 1 of three core symptoms Fluctuating cognition, visual hallucinations, and motor parkinsonism Criteria were expanded in 2005 Neuroleptic sensitivity and RBD Specific imaging findings on dopamine SPECT imaging or MIBG cardiac scintigraphy Dementia with progressive cognitive deficits that result in social and occupational dysfunction must be present for either probable or possible DLB Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:

PD Dementia Typically dementia occurs later in disease Must meet criteria for PD first Tremor Rigidity Akinesia/bradykinesia Postural instability

Manifestations at PD Onset Tremor at rest Bradykinesia Rigidity Micrographia Hypophonia Masked face Stooped, shuffling gait Slowing of activities of daily living Decreased arm swing when walking Barbosa et al. Psychiatr Clin North Am. 1997;20: Playfer. Postgrad Med. 1997;73:

Early Deficits in PD Fronto-striatal Syndrome Cognitive flexibility Planning Working memory Learning Prodrome to dementia? Kehagia AA et al., Lancet Neurol, 2010;9:

Mild Cognitive Impairment in PD 20% - 57% of patients are affected in 3-5 years of PD diagnosis PD as a fronto-striatal syndrome Deficits clear when patients need to act based on internal rather than external cues DA Dependent Flexibility, switching between known tasks, working memory DA Independent Mental rotation, verbal memory Kehagia AA et al., Lancet Neurol, 2010;9:

PD Dementia Diagnostic Criteria PDD associated with mortality Longitudinal estimates of its cumulative prevalence are 75% to 90% PD patients are three to five times more likely to develop dementia compared with healthy individuals Closely related to dementia with Lewy bodies Both are distinguishable from AD Lewy bodies, plaques, and vascular changes are present in both Different temporal profiles Kehagia AA et al., Lancet Neurol, 2010;9:

Diagnostic Criteria for PDD Diagnosis of PD by the Queen Square brain bank criteria PD precedes dementia onset MMSE score of <26 Severe cognitive dysfunction that interferes with daily living Impairment on at least tow Three-word recall (MMSE) Overlapping pentagons (MMSE) Months reverse or sevens backward (MMSE) Lexical fluency Clock drawing Absence of major depression, delirium, or other abnormalities that obscure diagnosis

Neuropsychological Deficits in PDD Executive Wisconsin card sorting test; Stroop performance; Odd-Man- Out, verbal fluency Working Memory Digit and spatial span Memory Free and cued recall, auditory verbal learning Visuospatial Abilities Clock drawing, Benton line orientation, face recognition, fragmented letters

Key Points : LBDD vs PAD LBDD presents with dementia early on in the disease LBDD are more likely to have hallucinations, delusions early on in disease course LBDD have fewer Parkinsonian symptoms PAD must meet criteria for PD, dementia occurs later in disease course

Pathophysiology LBDD Lewy Bodies- eosinophilic inclusion bodies Present in brainstem and cerebral cortex See changes in basal ganglia>>reduction in # of cholinergic projections to thalamic reticular nucleus>> reduction in cholinergic neurotransmission Specific to LBD: correlation between hallucinations, staring spells and decreased cholinergic function

Pathophysiology LBDD Nagahama et al found SPECT scan studies of 145 DLB patients revealed: Visual hallucinations- hypoperfusion of parietal- occipital association cortices Misidentifications- hypoperfusion of the limbic- paralimbic structures Delusions- hypoperfusion of the frontal cortices

Pathophysiology of PAD See loss of pedunculopontine cholinergic neurons>>loss of dopamine, norepinephrine or acetylcholine neurotransmitters May see inability of ACH transporting ions to bind to receptors Als0 see presence of abnormal tau genes

Imaging in PD Dementia Amyloid Imaging Cortical amyloid deposition is significantly increased in DLB Amyloid burden in PDD and PD-ND similar PDD subjects shown to have significantly decreased PiB binding compared to AD or DLB with similar dementia severity Occipital cortex Severely compromised in DLB, PDD and PD-ND Relative sparing in AD Silbert LC et al., Brain Path, 2010;20:

Clinicopathologic Spectrum of Dementia Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:

Cognitive Impairment in PD Cholinesterase Inhibitors Studied in DLB and PDD Provide benefit in treating cognitive and neuropsychiatric symptoms Types: Rivastigmine approved in 2006 Donepezil Galantamine Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:

Cognitive Impairment in PD Treatment Strategies Rivastigmine Dual acetylcholinesterase and butyrylcholinesterase inhibition Improved apathy, anxiety, delusions nad hallucinations in DLB patients Improved ADL in PDD relative to baseline Only stabilize AD patients Kehagia AA et al., Lancet Neurol, 2010;9:

Cognitive Impairment in PD Treatment Strategies Donepezil Acetylcholinesterase inhibition Tested in smaller studies Improve cognition as measured by MMSE Did not exacerbate parkinsonism Kehagia AA et al., Lancet Neurol, 2010;9:

Cognitive Impairment in PD Treatment Strategies Memantine Originally tested as a PD treatment Glutamatergic compound Non-competitive antagonist of nicotinic acetylcholine receptors 2009 test in PDD and DLB Improved MMSE and global change score Ameliorated cognition in PDD May have differential therapeutic responsivity Kehagia AA et al., Lancet Neurol, 2010;9:

Mild Cognitive Impairment in PD Atomoxetine Norepinephrine reuptake inhibitor Recent open-label study Improvements in clinicians global impression of change and executive function AEs included gastrointestinal disturbance One patient exhibited hypermania Further studies are needed Burn DJ et al., Brain Path, 2010;20:

Mild Cognitive Impairment in PD Safinamide Dopaminergic and glutamatergic properties Undergoing evaluation in early and late PD Preliminary study suggest some benefit on executive dysfunction in early PD Burn DJ et al., Brain Path, 2010;20:

Cognitive Impairment in PD Treatment Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:

Treatment Options LBDD Acetylcholinesterase Inhibitors Atypical neuroleptics Antidepressants Dopaminergic agents Agonists Carbidopa/levodopa

Treatment Options LBDD Benzodiazepines Antiepileptics Gingko baloboa

Nonpharmacologic Options LBDD/PAD No approved surgery (DBS) Keep routine Door alarms/chimes Geropsychiatric evaluation/home health

Nonpharmacologic Treatment PAD/LBDD Exercise?? Music therapy Yoga/tai chi Cognitive exercises Adequate nutrition

Disease Course PAD More predictable than DLBD as dementia occurs later in disease course If cognitive issues are due to medication side effects then often controllable or even reversible Adjust PD meds Exclude underlying infection Treat with atypical antipsychotic

PD Dementia Visual Hallucinations Predict rapid cognitive deterioration and dementia onset Associated with cortical Lewy bodies Temporal regions Hippocampal atrophy associated with verbal learning deficits in PDD patients having hallucinations Patients with visual hallucinations also have frontal hypermetabolism and orbitofrontal atrophy that correlates with visual memory deficits Kehagia AA et al., Lancet Neurol, 2010;9:

Disease Course in LBDD Disease symptoms fluctuate Harder to control More sensitive to medications As dementia occurs earlier on in illness, pts often require assistive care earlier

Caregiver Support Local support groups Websites: wemove.org pda.org lbda.org clincialtrials.gov Home physical therapy, nursing etc. Strong social support group

Defining Characteristics Kurtz AL et al., Curr Treat Opt Neuro, 2011;13:

Take Home Points Both LBDD and PAD patients should be on an acetylcholinesterase inhibitor early on- TREAT EARLY! Providing the caregiver with support is essential Further research is needed to identify biomarkers to distinguish PAD from DLBD Earlier diagnosis of PD may delay onset of PAD